Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting

SAN FRANCISCO, April 30, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host an analyst and investor event with clinical investigators on Saturday, June 2, 2018 at 6:45 p.m. CDT in Chicago, IL during the 2018 American Society of Clinical Oncology (ASCO) Meeting. The event will immediately follow the oral presentation of preliminary Phase 1/2 results of PIVOT, a study of NKTR-214 in combination with nivolumab, during the Developmental Therapeutics – Immunotherapy session at the ASCO meeting.

NKTR-214 is an investigational immune-stimulatory therapy designed to expand specific cancer-fighting CD8+ effector T cells and natural killer (NK) cells directly in the tumor micro-environment and increase expression of PD-1 on these immune cells.

Clinical investigators at the event will include Dr. Adi Diab, Assistant Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, Dr. Scott N. Gettinger, Associate Professor, Medical Oncology at the Yale Cancer Center and Dr. Nizar M. Tannir, Professor, Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center.

Investors and analysts are invited to listen to a live audio webcast of the event which will be accessible from the home page of the company's website The webcast will also be available for replay for two weeks following the event.

Details of the oral presentation for PIVOT results at ASCO are as follows:

Oral Presentation
Date: Saturday, June 2, 2018, Presentation Time: 5:00 p.m. Central Daylight Time
Session Title: Developmental Therapeutics – Immunotherapy
Presentation Title: NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT
Presenter: Dr. Adi Diab, MD Anderson Cancer Center
Location: McCormick Place, Hall B1

About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements which can be identified by words such as: "will," "designed" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the expected benefits of NKTR-214.  Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) NKTR-214 is in early stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied prior to regulatory approval due to lack of sufficient efficacy, safety considerations or other factors that impact drug development; (ii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of potential new drug candidates such as NKTR-214 is therefore very uncertain and unpredictable and could fail; (iii) patents may not issue from our patent applications for our drug candidates including NKTR-214, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (iv) certain other important risks and uncertainties set forth in Nektar's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on March 1, 2018. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Nektar Contacts:

For Investors: 
Jennifer Ruddock of Nektar Therapeutics

For Media:
Jodi Sievers of Nektar Therapeutics

Dan Budwick of 1AB


SOURCE Nektar Therapeutics

Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide